NCT02605720View on ClinicalTrials.gov

Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns

PHASE3CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

February 29, 2016

Conditions
Malaria
Interventions
DRUG

Dihydroartemisinin-piperaquine

DHA/PPQ dose 2.1/17.1 mg/Kg daily for 3 days (PNG National Malaria Treatment Protocol) monthly for 3 months

Trial Locations (1)

Unknown

Lihir medical Centre, Londolovit

Sponsors
All Listed Sponsors
collaborator

Walter and Eliza Hall Institute of Medical Research

OTHER

collaborator

Papua New Guinea Institute of Medical Research

OTHER_GOV

collaborator

Barcelona Institute for Global Health

OTHER

lead

Lihir Medical Centre

OTHER